Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...